Adverse Effects Associated With Hypophosphatemia

Panelists discuss how hypophosphatemia can cause both acute effects like muscle weakness and confusion and chronic complications such as osteomalacia and metabolic disturbances, potentially impacting patients’ mobility, energy levels, and overall quality of life if not properly monitored and managed.

EP: 1.Background and Causes of Iron Deficiency Anemia

EP: 2.Pathophysiology of Iron Deficiency Anemia

EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia

EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia

EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis

EP: 6.Oral vs IV Iron in Clinical Practice

EP: 7.FDA-Approved IV Iron Formulations

EP: 8.Factoring in Safety Considerations With IV Iron Products

Now Viewing

EP: 9.Adverse Effects Associated With Hypophosphatemia

EP: 10.Clinical Impact of Hypophosphatemia

EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron

EP: 12.Adherence and Time Spent Receiving IV Iron Infusions

EP: 13.Step Edits Associated with IV Iron Therapies

EP: 14.The Future of IV Iron Administration

EP: 15.Closing Thoughts on Iron Deficiency Anemia

Video content above is prompted by the following:

• What are the short- and long-term effects of hypophosphatemia? How do these impact patients’ daily lives?

Related Videos

Related Content

Advertisement

July 11th 2025

GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer

Brooke McCormick

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 10th 2025

SGLT2 Inhibitor Offers Kidney Protection and Reduces Heart Failure Risk After Acute Myocardial Infarction

Giuliana Grossi

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

July 8th 2025

Encounter-Level Factors Drive Racial Disparities in COVID-19 Treatment Access

Brooke McCormick

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.

Related Content

Advertisement

July 11th 2025

GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer

Brooke McCormick

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 10th 2025

SGLT2 Inhibitor Offers Kidney Protection and Reduces Heart Failure Risk After Acute Myocardial Infarction

Giuliana Grossi

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

July 8th 2025

Encounter-Level Factors Drive Racial Disparities in COVID-19 Treatment Access

Brooke McCormick

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.